Travellers at the mainland Chinese border in Shenzhen. China reopened its borders for international travel on Sunday and will roll out more pro-growth measures to steady the economy. Photo: Dickson Lee
Citigroup says big pharma preferred by foreign investors as China reopens, appetite for pre-revenue biotech firms wanes
- Foreign investors are looking for firms with a track record of profit making and direct beneficiaries of China’s reopening, Citi analyst says
- So-called chapter 18A companies may not benefit much as their financial figures are not solid, Everbright Securities analyst says
